Exonate Adds Dr. Rafiq Hasan to Leadership Team

Exonate announced the expansion of its Board with the appointment of Dr. Rafiq Hasan as Non-Executive Director. This strategic move aims to bolster the company's expertise in ophthalmology, particularly within the diabetic eye disease sector, as it advances its lead candidate, EXN407, toward Phase IIb clinical trials.

Bringing Extensive Experience to Exonate's Board

Dr. Rafiq Hasan brings a wealth of experience from the global pharmaceutical industry, with a focus on ophthalmology and diabetic eye diseases. Currently serving as CEO of Complement Therapeutics, a company specializing in next-generation complement medicines, Dr. Hasan's leadership extends to various board and advisory roles, including positions at Oxular and BioGeneration Ventures.

"With his proven track record of success and deep understanding of diabetic eye diseases, Dr. Hasan is an invaluable addition to Exonate's Board of Directors," stated Catherine Beech, CEO of Exonate. "His insights and expertise will play a crucial role as we advance EXN407, our lead candidate, through clinical development."

Dr. Hasan's Enthusiasm for Advancing Innovative Therapies

Dr. Hasan expressed his enthusiasm for joining Exonate's Board, highlighting the potential of EXN407 to revolutionize treatments for diabetic eye diseases. "I am excited to collaborate with Catherine and the team at Exonate to drive forward the development of innovative therapies that could significantly improve outcomes for patients," he commented.

Advancing EXN407: Addressing Critical Unmet Needs

Exonate's lead candidate, EXN407, a small molecule SRPK1 inhibitor, represents a novel topical therapy for diabetic eye diseases, including diabetic retinopathy and diabetic macular edema. With plans to initiate a CLEAR-DM (Clinical Evaluation of a New Eyedrop for Alleviating Retinopathy in Diabetic Macular Edema) Phase IIb clinical trial in 2024, Exonate aims to address critical unmet needs in the management of these sight-threatening conditions.

The appointment of Dr. Rafiq Hasan underscores Exonate's commitment to advancing innovative treatments for retinal vascular diseases, with a focus on improving patient outcomes and quality of life.